Hot Investor Mandate 3: Strategic Oncology Fund Invests in New Drugs from Discovery to Preclinical Stage

27 Jul

A $50 million strategic corporate venture capital fund formed by an oncology-focused pharmaceutical company seeks to make equity investment in startup companies that discover and develop innovative therapeutic products and/or drug-enabling platform technologies that demonstrate a clear potential to benefit cancer patients. Investment size can be flexible depending on the deal. The firm will also consider the option-type of investments and spin-outs, in addition to pure equity investments. The fund is currently seeking opportunities in the U.S., Europe and Japan. and opportunities mainly in US and Europe.

The firm considers a wide variety of modalities (both biologics and small molecules) within the oncology field. The firm focuses on programs from drug discovery to preclinical development.

The firm is looking for teams with strong sector expertise. With the support of the parent company’s established expertise in the field of oncology product discovery and development, the firm will provide financial resources and company outreach to build strategic alliances to help translate novel research and high potential drug candidates into cornerstone products. The firm may request regional option or rights on a case-by-case basis.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: